Squadron Capital Llc Sells 16,300 Shares of OrthoPediatrics (NASDAQ:KIDS) Stock

OrthoPediatrics Corp. (NASDAQ:KIDS) major shareholder Squadron Capital Llc sold 16,300 shares of the firm’s stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $24.74, for a total value of $403,262.00. Following the transaction, the insider owned 6,881,464 shares in the company, valued at $170,247,419.36. The trade was a 0.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Squadron Capital Llc also recently made the following trade(s):

• On Wednesday, August 26th, Squadron Capital Llc sold 18,000 shares of OrthoPediatrics stock. The stock was sold at an average price of $24.28, for a total value of $437,040.00.
• On Monday, August 24th, Squadron Capital Llc sold 4,000 shares of OrthoPediatrics stock. The stock was sold at an average price of $25.75, for a total value of $103,000.00.

OrthoPediatrics Price Performance

KIDS opened at $23.32 on Friday. The company has a market capitalization of $608.89 million, a price-to-earnings ratio of -13.88 and a beta of 0.98. The company has a current ratio of 4.78, a quick ratio of 2.17 and a debt-to-equity ratio of 0.28. OrthoPediatrics Corp. has a 12-month low of $14.42 and a 12-month high of $26.74. The business’s fifty day simple moving average is $21.32 and its 200-day simple moving average is $18.62.

OrthoPediatrics (NASDAQ:KIDS) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.04. OrthoPediatrics had a negative return on equity of 8.10% and a negative net margin of 15.72%.The firm had revenue of $70.51 million during the quarter, compared to the consensus estimate of $68.21 million. On average, equities research analysts anticipate that OrthoPediatrics Corp. will post -1.14 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the stock. Piper Sandler reiterated an “overweight” rating and set a $25.00 price objective (up from $22.00) on shares of OrthoPediatrics in a research note on Wednesday, August 5th. Weiss Ratings raised shares of OrthoPediatrics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, August 5th. TD Cowen restated a “buy” rating on shares of OrthoPediatrics in a report on Monday, June 15th. Truist Financial set a $22.00 target price on OrthoPediatrics in a research report on Wednesday, August 5th. Finally, Needham & Company LLC boosted their price target on OrthoPediatrics from $30.00 to $35.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Nine analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $26.44.

OrthoPediatrics News Summary

Here are the key news stories impacting OrthoPediatrics this week:

• Positive Sentiment: OrthoPediatrics completed the full U.S. commercial launch of its 3P™ Pediatric Plating Platform® Hip System after more than 350 successful implantations during its limited release. The system expands the company’s pediatric trauma and deformity portfolio and could create a long-term revenue and market-share opportunity, though management did not provide specific financial guidance. 3P Pediatric Plating Platform Hip System launch
• Positive Sentiment: Analyst sentiment remains favorable. Piper Sandler raised its target to $25, Needham lifted its target to $35, and BTIG increased its target to $29, while maintaining positive ratings. MarketBeat data shows a “Moderate Buy” consensus with an average target of $26.44.
• Positive Sentiment: Recent quarterly results exceeded expectations: OrthoPediatrics reported a loss of $0.26 per share versus the estimated loss of $0.30, while revenue of $70.51 million surpassed the $68.21 million consensus estimate. BlackRock and other institutional investors also recently initiated or expanded positions.
• Neutral Sentiment: Reported short interest was listed at zero shares, but an invalid change figure makes the data unreliable and limits its usefulness for assessing short-selling pressure.
• Negative Sentiment: Director David R. Pelizzon and major shareholders associated with Squadron Capital and Jennifer N. Pritzker sold a combined 38,300 shares for approximately $943,302 across August 24–26, at prices ranging from $24.28 to $25.75. The sales reduced their position by roughly 0.56%, leaving ownership of about 6.86 million shares. While modest relative to their remaining stake, repeated insider selling may weigh on investor sentiment, particularly with the stock near its 52-week high. SEC insider transaction filing

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the company. California State Teachers Retirement System raised its stake in shares of OrthoPediatrics by 397.1% during the 2nd quarter. California State Teachers Retirement System now owns 4,553 shares of the company’s stock worth $87,000 after acquiring an additional 3,637 shares in the last quarter. Nantahala Capital Management LLC acquired a new stake in OrthoPediatrics in the second quarter valued at approximately $4,636,002,000. Grandeur Peak Global Advisors LLC acquired a new stake in OrthoPediatrics in the second quarter valued at approximately $954,000. Bank of America Corp DE purchased a new position in OrthoPediatrics in the second quarter worth $268,000. Finally, AWM Investment Company Inc. purchased a new position in OrthoPediatrics in the second quarter worth $4,537,000. Hedge funds and other institutional investors own 69.05% of the company’s stock.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.